Sheikh, Aasim

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH

Loomba, R., Noureddin, M., Kowdley, K. V., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N., Caldwell, S. H., Goodman, Z., et al. (2021) · Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 296

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Harrison, S. A., Goodman, Z., Jabbar, A., Vemulapalli, R., Younes, Z. H., Freilich, B., Sheikh, M. Y., Schattenberg, J. M., Kayali, Z., Zivony, A., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 260

EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study

Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., et al. (2022) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 123

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial

Sims, M. D., Khanna, S., Feuerstadt, P., Louie, T. J., Kelly, C. R., Huang, E. S., Hohmann, E. L., Wang, E. E. L., Oneto, C., Cohen, S. H., et al. (2023) · JAMA Network Open

Clostridium difficile and Clostridium perfringens researchGut microbiota and health

Cited by 83

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study

Newsome, P. N., Palmer, M., Freilich, B., Sheikh, M. Y., Sheikh, A., Sarles, H., Herring, R., Mantry, P., Kayali, Z., Hassanein, T., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 80

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

Vuppalanchi, R., Caldwell, S. H., Pyrsopoulos, N., deLemos, A. S., Rossi, S., Levy, C., Goldberg, D. S., Mena, E. A., Sheikh, A., Ravinuthala, R., et al. (2022) · Journal of Hepatology

Liver Diseases and ImmunityPeroxisome Proliferator-Activated Receptors

Cited by 79

Safety and efficacy of combination therapies including cilofexor/ firsocostat in patients with bridging fibrosis and cirrhosis due to NASH: Results of the phase 2b ATLAS trial

Loomba, R., Noureddin, M., Kowdley, K., Kohli, A., Sheikh, A., Neff, G., Bhandari, B. R., Gunn, N. T., Caldwell, S., Goodman, Z., et al. (2020) · Journal of Hepatology

Liver Disease Diagnosis and TreatmentOrgan Transplantation Techniques and Outcomes

Cited by 9